Stock · GSK.L · Healthcare
United Kingdom · Large Cap · Revenue 12 mo. £33.2B
Price as of 11/06/2026
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Original text from the data provider
Summary
48.6 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €7.1B (2025), it supports €79.3B. The remaining €13B of the market value assume it grows 2.2% a year for 10 years and not at all afterwards.
Required FCF growth per year
2.2%
no growth afterwards
Price to operating cash flow 9.6×, within its usual range.
Middle half of 20 quarters: 7.3× to 9.9×, median 8.5×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
No anomaly in the stored figures.
Since the last quarter
Q1 → Q2 2026
4 more unchanged: Revenue, 12 mo., Gross margin, Net debt, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 34.90% | 11.52% | Rank 89 |
| Return on capital (Greenblatt) | 71.35% | 32.55% | Rank 83 |
| EBIT margin | 21.95% | 18.31% | Rank 68 |
| FCF margin | 18.23% | 14.12% | Rank 66 |
| Gross margin | 72.54% | 60.99% | Rank 75 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 4.11% | 8.04% | Rank 27 |
| Earnings growth, 3 years per year | −27.62% | 5.44% | Rank 7 |
| Earnings growth, 5 years per year | −0.54% | 7.00% | Rank 29 |
| Sustainable growth (ROE × retained earnings) | 4.13% | 3.66% | Rank 54 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 7.35% | 2.90% | Rank 93 |
| FCF yield | 7.73% | 3.63% | Rank 89 |
| EV/saleslower is better | 2.80 | 4.03 | Rank 63 |
| EV/EBITlower is better | 12.77 | 21.73 | Rank 84 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −3.34% | 8.66% | Rank 36 |
| Share price, 6 months | 3.03% | 24.27% | Rank 19 |
| Share price, 3 months | 1.54% | 15.42% | Rank 18 |
| Distance from 52-week high | −16.67% | −7.35% | Rank 25 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 7.07% | 0.30% | Rank 14 |
| Change in share countlower is better | −0.60% | 0.00% | Rank 62 |
| Dividend streak in years | 2 | 10 | Rank 36 |
| Price reaction to results, market-adjusted | −0.91% | 0.05% | Rank 37 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 26.80% | 48.40% | Rank 16 |
| Net debt/EBITDAlower is better | 1.23 | 1.11 | Rank 46 |
| Debt to equitylower is better | 1.08 | 0.48 | Rank 18 |
| Volatility, 1 yearlower is better | 24.88% | 31.42% | Rank 90 |
Ten years in figures
| Year | Revenue, £B | EBIT margin | FCF, £B | Shares | Net debt, £B |
|---|---|---|---|---|---|
| 2016 | 27.9 | 24.5% | 4.1 | 3.93B | 13.9 |
| 2017 | 30.2 | 26.4% | 4.7 | 3.95B | 13.3 |
| 2018 | 30.8 | 26.0% | 6.6 | 3.98B | 22.2 |
| 2019 | 33.8 | 23.1% | 5.9 | 4.01B | 26.0 |
| 2020 | 34.1 | 24.0% | 6.2 | 4.03B | 21.1 |
| 2021 | 24.7 | 21.9% | 5.0 | 3.24B | 20.1 |
| 2022 | 29.3 | 22.8% | 5.1 | 4.08B | 17.5 |
| 2023 | 30.3 | 23.1% | 4.4 | 4.11B | 15.3 |
| 2024 | 31.4 | 18.1% | 3.6 | 4.14B | 13.3 |
| 2025 | 32.7 | 22.0% | 6.0 | 4.12B | 14.6 |
Score, radar and strategy match for GSK plc are visible with Plus. Metrics, price and sector comparison stay free.
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
The match with the 18 strategies checked is visible with Plus.
Selected fundamental metrics for GSK plc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 13.6 | 30.0 |
| P/B ratio | 4.8 | 4.8 |
| Return on equity (ROE) | 34.9% | 11.5% |
| Equity ratio | 26.8% | 48.4% |
| Debt-to-equity (D/E) | 1.08 | 0.48 |
| Dividend yield | 3.6% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| GSK.L | GSK plcthis page | |
| AZN.L | AstraZeneca PLC | locked |
| SAN.PA | Sanofi SA | locked |
| BMY | Bristol-Myers Squibb Company | locked |
| 4519.T | Chugai Pharmaceutical Co. Ltd. | locked |
| BAYN.DE | Bayer AG | locked |
30 days free with all indices, then with Plus.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.